Studies in animal models showed that antitumor immune response can be induced by a variety of cancer vaccines. This may also occur in the clinic, but the immune response in vaccinated cancer patients was rarely associated with a significant clinical response. This chapter will discuss (a) the crucial issue of the most appropriate tumor antigens (self vs. mutated) to be used for vaccination in human solid tumors; (b) the different factors that may impair antitumor immune response; (c) the reasons for the last, successful wave of vaccination trials; and (d) the role of combined vaccination and immunomodulation in the treatment of solid tumors.
CITATION STYLE
Parmiani, G., Cimminiello, C., Maccalli, C., & Russo, V. (2015). Vaccination in human solid tumors: Recent progress in the clinical arena. In Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (pp. 41–46). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-662-46410-6_2
Mendeley helps you to discover research relevant for your work.